Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
ScinoPharm Lists On Taiwan Stock Market
by Jean-François Tremblay
October 10, 2011
| A version of this story appeared in
Volume 89, Issue 41
ScinoPharm, Taiwan’s largest producer of active pharmaceutical ingredients (APIs), has listed on the Taiwan Stock Exchange in a stock offering that values the company at $950 million. ScinoPharm raised $32 million from the listing to finance its expansion. More than half of the company is owned by the Taiwanese conglomerate Uni-President. ScinoPharm, which has headquarters in southern Taiwan, produces most of the APIs that the island exports. The company is completing construction of another facility in Changshu, Jiangsu province, China.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X